Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author does not hold a position in RXRX.
← Back to Free Index

RXRX

Analysis as of: 2026-09-28
Recursion Pharmaceuticals, Inc.
Clinical-stage biotech using its AI-native Recursion OS, automated labs, and proprietary multimodal data to develop internal and partnered small-molecule drug programs.
ai automation biotech healthcare software
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Clinical Proof Still Gates Platform Re-Rate
The upside case is real but path dependent: one internal asset plus cleaner partner monetization can move this from AI-enabled services toward multi-asset biotech economics. Near-term repricing still runs through November data and FDA clarity.

Analysis

Thesis
Recursion is a leveraged bet that proprietary biology data plus automated labs can turn falling AI costs into a multi-asset drug engine; if REC-4881 wins a credible approval path and partner economics shift toward licenses, milestones, and royalties, a 2-5x equity outcome by 2031 is plausible.
Last Economy Alignment
Cheaper models help Recursion because they plug into a proprietary data-and-lab loop, but value still has to clear clinical proof and FDA gates.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
3.9x (from 5 most recent analyses)
Reasoning
Upside comes from mix shift, not just more programs. The stock can rerate if the business stops looking like lumpy discovery services and starts looking like a repeatable engine that creates owned drug assets, partner milestones, model licenses, and reusable data rights. I keep the case in the 2-5x range because proof is still concentrated in a few catalysts and the lead asset remains heavily regulator-gated.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The core risk is proof conversion, not AI output volume. Recursion must show that its data, automation, and models create approval-oriented assets often enough to support licenses, milestones, royalties, and eventual product revenue. If REC-4881 gets a workable registrational path and one more internal or partner program validates the engine, the business can rerate sharply; if not, it can remain a cash-consuming discovery vendor with recurring dilution risk.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.48
Cheaper AI helps because better models can plug into the same proprietary data factory and automated labs, making each experiment more valuable. But the score stops short of elite because regulators and human clinical outcomes still decide whether that loop creates durable cash flows.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$7.22
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case